This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maskin, C. S. Articles by Le Jemtel, T. H. Search for Related Content PubMed PubMed Citation Articles by Maskin, C. S. Articles by Le Jemtel, T. H.

Circulation, Vol 67, 1065-1070, Copyright © 1983 by American Heart Association

ARTICLES

Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure

CS Maskin, L Sinoway, B Chadwick, EH Sonnenblick and TH Le Jemtel

The hemodynamic and clinical effects of WIN 47203, a newly synthesized noncatecholamine, nonglycosidic inotropic agent, were studied in 11 patients with severe chronic congestive heart failure. Intravenous WIN 47203 increased cardiac index from 1.93 +/- 0.36 to 2.87 +/- 0.45 l/min/m2 (p less than 0.001) and reduced pulmonary capillary wedge pressure from 27.0 +/- 8.4 to 16.3 +/- 6.1 mm Hg (p less than 0.001). Mean systemic arterial pressure decreased from 75.2 +/- 6.7 to 72.4 +/- 6.3 mm Hg (p less than 0.01) and systemic vascular resistance from 1591 +/- 397 to 1071 +/- 293 dyn-sec-cm5 (p less than 0.001); heart rate was unchanged. Oral WIN 47203 produced similar hemodynamic improvement. Hemodynamic monitoring of six consecutive doses did not demonstrate evidence for attenuation of effectiveness. Chronic therapy with WIN 47203 produced substantial symptomatic improvement and increased maximal oxygen uptake at 1 week. Patients were further improved after 4 weeks of WIN 47203, and maximal oxygen uptake increased from 9.0 +/- 1.9 to 11.6 +/- 2.5 ml/kg/min (p less than 0.01 vs control). No overt clinical or laboratory manifestations of toxicity were observed. Withdrawal of WIN 47203 in two patients in whom clinical benefit was not sustained resulted in clinical and hemodynamic deterioration, which was reversed by reinstitution of the drug. Therefore, this study demonstrates the acute and sustained cardiotonic efficacy of WIN 47203 in man. If long-term administration remains well tolerated and without side effects, this drug appears to be very promising for treatment of chronic severe congestive heart failure.

This article has been cited by other articles:

				J. N. Cohn Inotropic therapy for heart failure: paradise lost Eur. Heart J., December 2, 2009; 30(24): 2965 - 2966. [Full Text] [PDF]

				A. Tsunoo and M. Kamijo Non-Cyclic AMP-Dependent, Positive Inotropic Cyclodepsipeptides with Negative Chronotropy J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1006 - 1012. [Abstract] [Full Text]

				J. J. Liu, L. A. Doolan, B. Xie, J. R. Chen, and B. F. Buxton DIRECT VASODILATOR EFFECT OF MILRINONE, AN INOTROPIC DRUG, ON ARTERIAL CORONARY BYPASS GRAFTS J. Thorac. Cardiovasc. Surg., January 1, 1997; 113(1): 108 - 113. [Abstract] [Full Text]